ColoFact is developing a point-of-care medical device that utilizes a simplified faecal sampling method to detect precancerous polyps and early-stage colorectal cancer, providing immediate results. This approach aims to increase screening participation rates, addressing the low current rates and potentially saving the European Union €3 billion annually through early detection.
Funding
$110K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Colorectal cancer screening programs suffer from low participation rates due to inconvenient and time-consuming traditional testing methods. This leads to delayed diagnoses and increased healthcare costs.
Solution
ColoFact was developing a point-of-care medical device designed to simplify fecal sampling and provide immediate results for the detection of precancerous polyps and early-stage colorectal cancer. The device aimed to replace existing inconvenient screening methods with a user-friendly approach, thereby increasing participation rates in screening programs. By providing immediate results, the device sought to enable earlier detection and intervention, improving patient outcomes and reducing healthcare expenditures. The device was intended to be a more convenient and less time-consuming alternative to current screening options.
Target Audience
The target audience included individuals eligible for colorectal cancer screening programs and healthcare providers seeking to improve screening participation rates.
Features
- Simplified fecal sampling method for ease of use.
- Point-of-care device providing immediate results.
- Designed for early detection of precancerous polyps and early-stage colorectal cancer.